Merck presents new data evaluating efficacy and safety of investigational islatravir in combination with doravirine

Merck presents new data from ongoing Phase 2b clinical trial evaluating efficacy and safety of investigational islatravir in combination with doravirine through 144 weeks for HIV-1 treatment at EACS 2021

HIV Treatment

October 27, 2021

Islatravir combined with doravirine continued to maintain viral suppression for people who had not previously received treatment

Read the full press release here.

Source : Merck

Related HIV and Co-Infections News

June 30, 2026
Infectious Disease Advisor: Single-tablet BIC/LEN noninferior to BIC/FTC/TAF in suppressed HIV
June 28, 2026
AVAC: New analysis shows decline in PEPFAR-supported HIV treatment; post-PEPFAR future in South Africa
June 25, 2026
Infectious Disease Advisor: Antiretroviral therapy linked to increased diabetes risk in HIV

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.

Merck presents new data evaluating efficacy and safety of investigational islatravir in combination with doravirine

Related HIV and Co-Infections News

Infectious Disease Advisor: Single-tablet BIC/LEN noninferior to BIC/FTC/TAF in suppressed HIV

AVAC: New analysis shows decline in PEPFAR-supported HIV treatment; post-PEPFAR future in South Africa

Infectious Disease Advisor: Antiretroviral therapy linked to increased diabetes risk in HIV

Get involved

Subscribe